Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.
AUTOR(ES)
Civitico, G
RESUMO
Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163287Documentos Relacionados
- Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.
- Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid.
- Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro.
- Inhibition of replication of hepatitis B virus by cytallene in vitro.
- Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro.
